http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2409599

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't
endingPage 342
issn 0724-4983
1433-8726
issueIdentifier 3
pageRange 337-342
publicationName World Journal of Urology
startingPage 337
bibliographicCitation Hendricksen K, van der Heijden AG, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Smits GAHJ, Puri R, Gruijs S, Witjes JA. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World Journal of Urology. 2009 Feb 13;27(3):337–42. doi: 10.1007/s00345-009-0382-4.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9be5c7ec1bbab7dad99e6586b12137c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e10e1da7e3cc978f89720bf9fb39cec
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8720bba616db6cffa94c45e13dfbfa3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eabe2fdbc1e5ee0dbb638352b6ae02e5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a330a19540b3bebbe1d947216b7f1871
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1778fd3023c89917ca047a80a8515a81
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98f41bffeb8e217455b799439716b09f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2fecd9ef9f1ba9ab2f5671c6a94fd042
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e13446fde8f98d93e7cace689af2147b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_363d2e755ed0fbfa5e322e5f5ad136e6
date 2009-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1007/s00345-009-0382-4
https://pubmed.ncbi.nlm.nih.gov/PMC2694322
https://pubmed.ncbi.nlm.nih.gov/19214526
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2429
https://portal.issn.org/resource/ISSN/1433-8726
https://portal.issn.org/resource/ISSN/0724-4983
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
discusses http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0002076
http://id.nlm.nih.gov/mesh/M0507513
http://id.nlm.nih.gov/mesh/M0448777
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c7b30a124b48c3f1dfc32b00e7637ba3
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8001188526048445b80af464c1079577
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7053
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5813717
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7173

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128662584
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135989295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129735276
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127481953

Total number of triples: 46.